Latest 20-F annual reports

NYSE
Lufax Holding Ltd reported a net loss of RMB3.6 billion in 2024, a significant decline from previous profits, driven by increased credit risk exposure and investment losses, alongside a business model transformation.
NASDAQ
Nova Ltd. achieved record product and service sales, profitability, and earnings per share in 2025, driven by strategic acquisitions and diversified metrology solutions.
NASDAQ
New Century Logistics (BVI) Limited reported a significant net loss of $10.73 million for fiscal year 2025, driven by reduced customer orders and increased operating expenses.
NASDAQ
Globavend Holdings Limited announced a significant 42.5% revenue increase to $23.56 million for fiscal year 2025, but net income fell by 49% and the company faces Nasdaq delisting due to its share price falling below minimum requirements.
NASDAQ
SCHMID Group N.V. reports a significant net loss in 2024 due to listing expenses and market downturns, while securing new financing and forecasting growth for 2025 and 2026.
NYSE
Lloyds Banking Group plc announced a 12% increase in statutory profit before tax to £6.7 billion for 2025, alongside a 15% rise in ordinary dividends and a new £1.75 billion share buyback program.
OTC.Pink
LEET Inc. announced a significant reduction in net loss and strong revenue growth for the fiscal year ended December 31, 2024, driven by white label projects and cost efficiencies, despite ongoing going concern uncertainties.
NYSE
British American Tobacco reports a 1.0% decline in reported revenue to £25.61 billion for 2025, alongside a significant 265% increase in reported operating profit driven by a Canadian litigation settlement credit.
NASDAQ
Smart Digital Group Limited reported a significant net loss of $37.85 million for fiscal year 2025, driven by share-based compensation and credit losses, with its shares suspended from trading on Nasdaq.
NYSE
AerCap Holdings N.V. reported a significant increase in net income to $3.8 billion in 2025, driven by strong asset sales and Ukraine conflict recoveries, alongside strategic fleet expansion.
NASDAQ
Skycorp Solar Group Limited reported a net loss of $2.21 million for fiscal year 2025, despite a significant increase in solar PV product sales, as HPC product sales declined and operating expenses rose.
NASDAQ
Ascendis Pharma A/S reported significant revenue growth in 2025, driven by strong global sales of YORVIPATH and SKYTROFA, while advancing its rare disease and oncology pipelines.
JM Group Limited announced significant revenue and net income growth for fiscal year 2025, despite an ongoing NYSE trading halt and SEC/NYSE investigations.
NYSE
Spotify Technology S.A. reported strong financial results for 2025, marked by significant user growth, increased Premium revenue, and a substantial rise in profitability.
NASDAQ
Farmmi, Inc. reported a significant net loss of $53.4 million for fiscal year 2025, a sharp decline from the previous year, driven by reduced agricultural product sales and substantial impairment and credit loss allowances, despite new logistics revenue.
NYSE
Barclays PLC announces two new independent non-executive director appointments, provides comprehensive details on its ordinary shares, ADRs, and debt securities, and updates its Group Securities Dealing Code.
BTS
Barclays Bank PLC announced a 25% increase in profit before tax for 2025, driven by robust performance in Global Markets and US Consumer Bank, despite rising credit impairment charges and ongoing regulatory challenges.
NASDAQ
InMode Ltd. reported a 6% revenue decrease to $370.5 million for fiscal year 2025, driven by reduced demand for aesthetic procedures, despite new product introductions and international growth.
NASDAQ
Rich Sparkle Holdings Limited reported a significant decrease in net income for fiscal year 2025, while outlining ambitious plans for AI integration and U.S. market expansion, alongside a substantial acquisition and private placement.
NYSE
Novo Nordisk reports 6.4% sales growth in 2025, driven by obesity and diabetes care, but anticipates a sales decline in 2026 due to increased competition and pricing pressures.
NASDAQ
ZK International Group Co., Ltd. reported a net loss of $4.02 million for fiscal year 2025 on significantly reduced revenue, while successfully raising $20.92 million in a private placement post-period.
NYSE
Novartis AG delivered robust financial performance in 2025, driven by strong sales of key innovative medicines and strategic acquisitions, despite facing generic competition for several established products.
NASDAQ
Mega Fortune Company Limited announced a significant increase in revenue and net income for fiscal year 2025, following its successful NASDAQ initial public offering.
NASDAQ
Integrated Media Technology Limited reported a net loss of $268,377 for 2025, accumulated losses of over $54 million, and received a going concern warning, while also facing Nasdaq delisting threats for non-compliance and low bid price.
NASDAQ
Kandal M Venture Limited filed an amendment to its annual report, confirming the effectiveness of its disclosure controls and procedures as of March 31, 2025, in response to SEC comments.
OTC.Pink
CordovaCann Corp. reported a widened net loss for fiscal year 2025 despite revenue growth, driven by significant asset impairments and ongoing operational challenges, while also disclosing ineffective internal controls.
NASDAQ
WF International Limited reported a net loss of $3.3 million for fiscal year 2025, a significant decline from previous profits, driven by a challenging real estate market and increased operating costs.
NASDAQ
WORK Medical Technology Group reported a net loss of $1.2 million for fiscal year 2025, with revenue decreasing by 14.4% to $9.8 million, while pursuing new medical device approvals and strategic partnerships.
NASDAQ
CN Energy Group Inc. reports a net loss of $11.1 million for fiscal year 2025, faces Nasdaq delisting, and shifts strategic focus to North American robotics and energy sectors.
NASDAQ
Origin Agritech Limited reported a substantial net loss of RMB 57.96 million for fiscal year 2025, alongside a going concern warning from its auditors, despite progress in biotechnology research and a recent capital raise.